Section Arrow
Quote
CORT.NASDAQ
- Corcept Therapeutics
Quotes are at least 15-min delayed:2026/08/02 09:41 EDT
Regular Hours
Last
 114.49
-3.83 (-3.24%)
Day High 
118.53 
Prev. Close
118.32 
1-M High
122.21 
Volume 
1.84M 
Bid
113
Ask
117.9
Day Low
111.79 
Open
118.11 
1-M Low
84.88 
Market Cap 
12.70B 
Currency 美元 
P/E 338.06 
%Yield -- 
10-SMA 95.72 
20-SMA 93.34 
50-SMA 82.62 
52-W High 122.21 
52-W Low 28.6601 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.35/4.45
Enterprise Value
12.71B
Balance Sheet
Book Value Per Share
5.94
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
761.41M
Operating Revenue Per Share
4.19
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.